Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome
- PMID: 26493280
- DOI: 10.1111/ene.12845
Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome
Abstract
Background and purpose: The influence of metabolic syndrome (MetS) on cognitive and affective functions in patients with Alzheimer's disease (AD) was examined.
Methods: A total of 570 AD patients were divided into two subgroups depending on waist circumference (WC) (normal versus achieving Japanese diagnostic criteria of MetS). Afterwards, the AD control subgroup was defined as those normal WC patients with no vascular risk factors (VRFs). The AD with MetS (AD-MetS) subgroup was defined as the MetS WC group who had two or more VRFs to qualify as having MetS. Cognitive and affective functions, insulin resistance, vascular endothelial function and white matter changes between AD-MetS and AD controls were compared.
Results: Scores on the Mini-Mental State Examination, Hasegawa Dementia Score-Revised, Frontal Assessment Battery and Montreal Cognitive Assessment were worse in the AD-MetS group than in AD controls, but the difference was not significant. Some analyses were conducted twice, once including all patients and once including only late-elderly patients. Scores on the Geriatric Depression Scale were found to be significantly higher for AD-MetS than for AD controls (all ages, late-elderly), as were those for apathy (late-elderly). Furthermore, both the homeostasis model assessment of insulin resistance and reactive hyperemia index scores were significantly worse in AD-MetS than in AD controls, whilst white matter changes showed a tendency to be worse.
Conclusions: Greater cognitive and affective decline occurs in patients with AD-MetS than in those without. Further, insulin resistance and vascular endothelial dysfunction are strongly correlated with AD-MetS before pathological white matter changes can be observed.
Keywords: Alzheimer's disease; cognitive/affective functions; insulin resistance; metabolic syndrome; vascular endothelial function; vascular risk factors.
© 2015 EAN.
Comment in
-
Does metabolic syndrome impact cognition and emotion in Alzheimer's disease?Eur J Neurol. 2016 Feb;23(2):237-8. doi: 10.1111/ene.12879. Epub 2015 Oct 19. Eur J Neurol. 2016. PMID: 26482425 No abstract available.
Similar articles
-
Age-dependent cognitive and affective differences in Alzheimer's and Parkinson's diseases in relation to MRI findings.J Neurol Sci. 2016 Jun 15;365:3-8. doi: 10.1016/j.jns.2016.03.031. Epub 2016 Mar 29. J Neurol Sci. 2016. PMID: 27206864
-
[Impact of combined medial temporal atrophy and white matter lesions on the cognitive and emotional functions in Alzheimer's disease patients].Nihon Ronen Igakkai Zasshi. 2014;51(4):342-9. doi: 10.3143/geriatrics.51.342. Nihon Ronen Igakkai Zasshi. 2014. PMID: 25327368 Japanese.
-
Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer's dementia.Thromb Haemost. 2015 Nov 25;114(6):1230-40. doi: 10.1160/TH14-11-0938. Epub 2015 Aug 20. Thromb Haemost. 2015. PMID: 26289958
-
Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.Ageing Res Rev. 2010 Oct;9(4):399-417. doi: 10.1016/j.arr.2010.04.007. Epub 2010 May 2. Ageing Res Rev. 2010. PMID: 20444434 Review.
-
Metabolic syndrome and the risk of late onset Alzheimer's disease: An updated review and meta-analysis.Nutr Metab Cardiovasc Dis. 2021 Jul 22;31(8):2244-2252. doi: 10.1016/j.numecd.2021.03.020. Epub 2021 Apr 1. Nutr Metab Cardiovasc Dis. 2021. PMID: 34039508
Cited by
-
Biomimetic Nanocarrier Targeting Drug(s) to Upstream-Receptor Mechanisms in Dementia: Focusing on Linking Pathogenic Cascades.Biomimetics (Basel). 2020 Mar 20;5(1):11. doi: 10.3390/biomimetics5010011. Biomimetics (Basel). 2020. PMID: 32244941 Free PMC article. Review.
-
Protein restriction slows the development and progression of Alzheimer's disease in mice.Res Sq [Preprint]. 2024 Apr 24:rs.3.rs-3342413. doi: 10.21203/rs.3.rs-3342413/v2. Res Sq. 2024. Update in: Nat Commun. 2024 Jun 18;15(1):5217. doi: 10.1038/s41467-024-49589-z. PMID: 37790423 Free PMC article. Updated. Preprint.
-
Nanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on Dementia.Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520976761. doi: 10.1177/1533317520976761. Am J Alzheimers Dis Other Demen. 2020. PMID: 33307726 Free PMC article. Review.
-
Risk Prediction Performance of the Thai Cardiovascular Risk Score for Mild Cognitive Impairment in Adults with Metabolic Risk Factors in Thailand.Healthcare (Basel). 2022 Oct 7;10(10):1959. doi: 10.3390/healthcare10101959. Healthcare (Basel). 2022. PMID: 36292406 Free PMC article.
-
Alzheimer's Disease as the Product of a Progressive Energy Deficiency Syndrome in the Central Nervous System: The Neuroenergetic Hypothesis.J Alzheimers Dis. 2017;60(4):1223-1229. doi: 10.3233/JAD-170549. J Alzheimers Dis. 2017. PMID: 28946565 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical